Group 1 - Tarsus Pharmaceuticals has successfully launched Xdemvy (lotilaner) for Demodex blepharitis, achieving sales exceeding $100 million per quarter [1] - The company's selling, general, and administrative expenses (SG&A) have also increased alongside sales [1] - The company is pursuing a "Get Big Fast" strategy, which was previously rated as a buy in May [1] Group 2 - The article reflects the author's personal opinions and does not constitute investment advice [2] - The author holds a beneficial long position in Tarsus Pharmaceuticals through stock ownership or derivatives [2]

Group 1 - Tarsus Pharmaceuticals has successfully launched Xdemvy (lotilaner) for Demodex blepharitis, achieving sales exceeding $100 million per quarter [1] - The company's selling, general, and administrative expenses (SG&A) have also increased alongside sales [1] - The company is following a "Get Big Fast" strategy, which was previously rated as a buy [1]

Core Insights - Tarsus Pharmaceuticals has launched a direct-to-consumer TV campaign for its eyedrop Xdemvy (lotilaner) aimed at treating Demodex blepharitis, marking a significant marketing strategy just over a year after the product's launch [1] Company Summary - Tarsus Pharmaceuticals is actively promoting its product Xdemvy through a direct-to-consumer approach, indicating a shift towards more aggressive marketing tactics to enhance product visibility and sales [1]